DRI® Cotinine Assay For In Vitro Diagnostic Use 10018516 (3 x 18 mL Kit) 0394 (100 mL Kit) 0395 (500 mL Kit) Intended Use The DRI® Cotinine Assay is an in vitro diagnostic medical device intended for the qualitative An effort should be made to keep pipetted samples of gross debris; it is recommended that and semiquantitative determination of Cotinine in human urine at a cutoff level of 500 ng/mL. highly turbid specimens be centrifuged before analysis. Adulteration of the urine sample may This assay is intended as an aid in the detection of cotinine after use or exposure to tobacco cause erroneous results. If adulteration is suspected, obtain another sample and forward both products. specimens to the laboratory for testing. Summary and Explanation of the Test Handle all urine specimens as if they were potentially infectious. Tobacco smoking or passive inhalation of tobacco smoke results in the absorption of nicotine through the lungs and mucus membranes of the mouth. When nicotine is absorbed, it is readily Assay Procedure metabolized into cotinine as its major metabolite.1,2,3 Cotinine is detectable in the urine of Analyzers capable of maintaining a constant temperature, pipetting samples, mixing reagents, smokers even several days after the termination of smoking. measuring enzymatic rates at 340 nm and timing the reaction accurately can be used to perform this assay. Several methods, including the measurement of thiocyanate, carbon monoxide and cotinine, can be used to determine an individual’s smoking status.4,5,6 Measurement of either carbon Refer to the specific application instructions of each analyzer for chemistry parameters before monoxide or thiocyanate can give a false indication of tobacco use, as they may come from performing the assay. other environmental sources.7 Cotinine, on the other hand, can only be derived from the metabolism of nicotine, and is therefore the best indicator of smoking status.8 Quality Control and Calibration Qualitative analysis The DRI Cotinine Assay is a liquid, ready-to-use homogeneous enzyme immunoassay. For qualitative analysis of samples, use the 500 ng/mL calibrator as a cutoff level. The DRI The assay is based on competition between continine labeled with glucose-6-phosphate Cotinine Calibrator, which contains 500 ng/mL cotinine, is used as a cutoff reference for dehydrogenase (G6PDH) enzyme and free cotinine in the sample for a fixed amount distinguishing “positive” and “negative” samples. of cotinine-specific antibody binding sites. The enzyme G6PDH activity is determined spectrophotometrically at 340 nm by measuring its ability to convert nicotinamide adenine Semiquantitative analysis dinucleotide (NAD) to NADH. For semiquantitative analysis, use all calibrators. Reagents Good laboratory practice suggests the use of control specimens to ensure proper assay Antibody/Substrate Reagent: performance. Use controls near the cutoff calibrator to validate the calibration. Control results Contains mouse monoclonal anti cotinine antibody, glucose-6-phosphate (G6P) and must fall within established ranges as determined by your laboratory. If results fall outside nicotinamide adenine dinucleotide (NAD) in Tris buffer with sodium azide as a preservative. of established ranges, assay results are invalid. All quality control requirements should Enzyme Conjugate Reagent: be performed in conformance with local, state and/or federal regulations or accreditation Contains continine labeled with glucose-6-phosphate dehydrogenase (G6PDH) in Tris buffer requirements. with sodium azide as preservative. Results and Expected Values Additional Materials Required (sold separately): Qualitative results The 500 ng/mL calibrator is used as a Cutoff reference for distinguishing “positive” from Kit Description “negative” samples. A sample that exhibits a change in absorbance (∆A) value equal to or 0404 DRI Cotinine Calibrator Kit, 6 x 5 mL greater than the value obtained with the cutoff calibrator is considered positive. A sample 0460 DRI Cotinine Low Control, 5 mL that exhibits a change in absorbance (∆A) value lower than the value obtained with the cutoff 0470 DRI Cotinine High Control, 5 mL calibrator is considered negative. Precautions and Warnings Semiquantitative results This test is for in vitro diagnostic use only. The reagents are harmful if swallowed. A rough estimate of drug concentration in the samples can be obtained by running a standard curve with all calibrators and quantitating samples off the standard curve. This method can be Reagents used in the assay components contain ≤ 0.09% sodium azide. Avoid contact with skin used to determine dilutions for confirmation or for quality control purposes. When the estimated and mucous membranes. Refer to SDS for additional precautions, handling instructions, and samples concentration is greater than the highest calibrator the sample can be diluted in accidental exposure treatment. Negative Calibrator and retested. The assay range is from 300 ng/mL to 2000 ng/mL. BSA The reagents contain ≤ 0.2% bovine serum albumin (BSA). Avoid contact with skin and Limitations mucous membranes. Avoid inhalation. May cause skin or inhaled allergic reaction. 1. A positive result from this assay indicates only the presence of cotinine and does not Refer to SDS for additional precautions, handling instructions, and accidental exposure necessarily correlate with the extent of physiological and psychological effects. treatment. 2. A positive result by this assay should be confirmed by another non-immunological method such as GC or GC/MS. Do not use the reagents beyond their expiration dates. 3. The test is designed for use with human urine only. 4. It is possible that other substances and/or factors, e.g., technical, procedural issues Reagent Preparation and Storage or other cotinine-like compounds other than those investigated in the specificity study, The reagents are ready for use. No reagent preparation is required. All assay components, may interfere with the test and cause false results. when stored refrigerated, are stable until the expiration date indicated on the label. Typical Performance Characteristics In the case of accidental spill, clean and dispose of material according to your laboratory’s SOP, Typical performance results obtained on the Hitachi 717 analyzer are shown below.10 The results local, and state regulations. obtained in your laboratory may differ from these data. In the case of damaged packaging on arrival, contact your technical support representative Precision (refer to back page of this PI). Negative control, positive control and cutoff calibrator were tested using a modified NCCLS protocol. The test was run in qualitative and semiquantitative modes by testing all three levels Specimen Collection and Handling in replicates of 6, twice per day for 10 days. Collect urine specimens in plastic or glass containers. Testing of fresh urine specimens is suggested. Microgenics recommends the use of fresh urine specimens. If specimens do not receive an initial testing within 7 days, they should be kept frozen. Samples with a pH range from 4 to 9 are suitable for testing with this assay. Qualitative (mA/min) Compounds structurally unrelated to cotinine produced negative results at the concentrations Calibrator/ listed below: Within-run Precision Total Precision Control Compound Concentration (μg/mL) Mean SD %CV Mean SD %CV Acetaminophen 1000 300 ng/mL 404 2.2 0.5 404 2.7 0.7 Acetylsalicylic acid 1000 500 ng/mL 421 2.3 0.5 421 2.9 0.7 Amitriptyline 50 700 ng/mL 437 2.6 0.6 437 3.5 0.8 Amphetamine 1000 Benzoylecgonine 1000 Semiquantitative (ng/mL) Caffeine 100 Calibrator/ Within-run Precision Total Precision Control Codeine 1000 Mean SD %CV Mean SD %CV Diazepam 100 300 ng/mL 333 20.0 6.0 333 32.0 9.4 Doxylamine 500 500 ng/mL 510 27.9 5.5 510 38.6 7.6 Ephedrine 1000 700 ng/mL 716 36.4 5.1 716 50.4 7.0 Ibuprofen 500 Phenytoin 40 Accuracy d-Methamphetamine 100 One hundred and ninety-four samples were analyzed by the DRI Cotinine Assay and OTI AUTO-LYTE® Cotinine EIA using 500 ng/mL Cotinine as cutoff calibrator. All the samples were l-Methamphetamine 100 confirmed by GC/MS. The results obtained by both qualitative and semiquantitative modes are Morphine 1000 summarized below: Nortriptyline 50 Qualitative Oxazepam 500 Out of 194 samples, 112 samples were detected as positive and 60 samples as negative by both immunoassays. Phencyclidine 500 Pheniramine 50 DRI Cotinine DRI Cotinine Phenobarbital 1000 Assay Assay Primidone 50 + - + - Propoxyphene 1000 + 112 21* + 110 0 AUTO-LYTE® GC/MS Cotinine EIA Quinidine 200 - 1* 60 - 3** 81 Ranitidine 500 Secobarbital 1000 * GC/MS confirmed the result obtained by the DRI Cotinine Assay. ** Two out of the three discrepant samples were borderline positive. Theophylline 50 9 Semiquantitative 11-Nor-∆ -THC-9-COOH 10 Out of 194 samples, 114 samples were detected as positive and 63 as negative by both Valproic Acid 150 immunoassays. Uric Acid 200 DRI Cotinine DRI Cotinine Interference Assay Assay Endogenous and exogenous substances were studied for potential interference with the + - + - Cotinine Assay. No interference was observed in urine samples containing compounds at the concentrations listed below. Urine pH was also studied for possible interference. + 114 17* + 110 0 AUTO-LYTE® GC/MS Cotinine EIA Compound Concentration - 0 63 - 4* 80 Acetaminophen 100 μg/mL Acetone 1000 mg/dL * GC/MS confirmed the result obtained by the DRI Cotinine Assay. ** Two out of the four discrepant samples were borderline positive. Ascorbic Acid